JERUSALEM, Nov. 19, 2025 /PRNewswire/ — Rafa Laboratories, a global leader in Chemical, Biological, Radiological, and Nuclear hazards medical countermeasures and Biodefense, today announced it has been awarded with a landmark development contract by the Biomedical Advanced Research and Development Authority (BARDA), part of Administration for Strategic Preparedness and Response  at the U.S. Department of Health and Human Services (HHS), for the advanced development of a novel intramuscular (IM) formulation of tranexamic acid (TXA)—a potentially life-saving therapy for uncontrolled bleeding. The contract is valued at up to $186 million, including all option periods.

This pivotal collaboration, which represents Rafa’s second major contract with BARDA, addresses an urgent global need: a rapidly deployable, easy-to-administer treatment for hemorrhage in the critical prehospital setting.

 Addressing the Critical Window to Save Lives

Uncontrolled bleeding is the leading cause of preventable death following trauma, whether caused by accidents, mass-casualty events or in the battlefield. Caregivers need a tool which can be easily administered to a large number of casualties in a short period of time. TXA is an antifibrinolytic agent commonly used off label around the world to treat trauma bleeding in the pre-hospital and hospital space.

Landmark clinical studies performed in tens of thousands of individuals have demonstrated that TXA can significantly reduce mortality rates if administered quickly enough following trauma hemorrhagic injury.

“The clock starts ticking the moment a patient sustains a hemorrhagic injury, and the few minutes before reaching a hospital are the most critical ones,” said Roy Shay, Vice President of Biodefense at Rafa Laboratories. “Currently, TXA is typically administered intravenously (IV), which is challenging, time-consuming and requires training.  The need for trained individuals even greater in high-stress, or mass-casualty situations. Developing a new intramuscular TXA injection is a potential game-changer as it simplifies the administration process, especially if administered with an autoinjector.

As planned under the potential scope of this project, Rafa shall also develop a TXA autoinjector which will enable  professional as well as nonprofessional care givers to deliver this essential treatment instantly—dramatically increasing survival chances worldwide.”

“The IM route offers a fast, reliable, and user-friendly alternative for the existing IV administration, which can be extremely difficult in patients experiencing severe shock”.

BARDA and Rafa are Collaborating on a Comprehensive Development Approach

Rafa Laboratoriesis adopting a robust and integrated product development approach, which is planned to include formulation development, manufacturing scale-up, pre/clinical trials and a streamlined regulatory pathway designed to secure U.S. Food and Drug Administration (FDA) approval.

“Over the past four decades, Rafa has built a reputation for developing highly dependable medical countermeasures targeting acute, life-threatening conditions, mainly CBRN and pain management.” said Iddo Leshem, Chief Executive Officer of Rafa Laboratories. “The IM TXA development contract marks a strategic expansion of Rafa’s presence in acute trauma care. We are deeply committed to partnering with BARDA to accelerate the delivery of this urgently needed, life-saving solution to hundreds of thousands of patients across the globe”.

About Rafa Laboratories

Founded in 1937 and headquartered in Jerusalem, Israel, Rafa Laboratories is a global leader in biodefense and emergency medical solutions. For more than 40 years, Rafa has supplied medical countermeasure autoinjectors to the U.S. federal government, NATO allies, military forces, and civilian stockpiles worldwide, including its Midazolam 10 mg autoinjector (US-FDA approved under NDA #216359 since 2022) and Atropine autoinjector (US-FDA approved under NDA #212319 for 2 mg since 2018 and EUA # for 0.5 & 1 mg since 2017). The company’s expertise spans the entire value chain — from a robust R&D pipeline addressing emerging threats, to cGMP-compliant manufacturing and successful regulatory approvals from the U.S. FDA and European health authorities.

Rafa’s controlling shareholder, FIMI Opportunity Funds, is Israel’s leading private equity fund. With over 25 years of experience, FIMI manages assets of $7 billion and has completed nearly 100 investments globally.

This project has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number  75A50125C00018.

Media Contact:
Roy Shay
VP, Biodefense
Rafa Laboratories
roys@rafa.co.il 

SHANGHAI, Nov. 19, 2025 /PRNewswire/ — Texxon Holding Limited (Nasdaq: NPT) (the “Company” or “Texxon”), a leading provider of supply chain management services in the plastics and chemical industries in East China, today announced its financial results for the fiscal year ended June 30, 2025.

Mr. Hui Xu, Chief Executive Officer and Chairman of Texxon, commented: “We are pleased to report strong results for the fiscal year ended June 30, 2025. To align with evolving market conditions and the broader industry environment, we implemented a strategic shift in our sales and marketing efforts toward high-growth sectors such as automotive, new energy, and chemical industries. Leveraging our core strengths in basic chemicals and plastic particles, we expanded our sales team to further broaden our customer base, market coverage, and penetration across China.”

“The refinement of our basic chemical product portfolio contributed to an improved average selling price. Our plastic particle sales surged as sales volume increased in response to increased demand, driven by their expanded application in new fields such as automotive, new energy and chemical industries, despite a decline in selling prices. Collectively, these initiatives drove an 18.5% increase in overall revenue, highlighted by an 88.5% surge in plastic-particle sales, while basic-chemical sales slightly grew 1.5%.”

“We prioritized business scale and long-term customer relationships over short-term margin gains. While this strategy temporarily compressed gross margin and profit, we believe it will strengthen customer retention, stabilize cash flows, and support sustainable profitability over the long term.”

“We are accelerating the construction of a factory to manufacture polystyrene, including production lines, storage facilities, and supporting infrastructure, located in Henan Province, China (the “Henan Polystyrene Factory”), which is scheduled to begin production in the fourth quarter of 2025. Once operational, we expect it will enable us to better meet market demand and capture higher margins amid potential shortages in chemical and plastic raw materials.”

“Looking ahead, we remain committed to achieving profitable growth through enhanced operational efficiency, deeper customer relationships, and disciplined product portfolio and pricing strategies. We believe, these initiatives will support long-term shareholder value and position Texxon for continued growth in an increasingly dynamic market.”

Fiscal Year 2025 Financial Summary 

• Revenue was $797.15 million for fiscal year 2025, representing an increase of 18.5% from $672.66 million for fiscal year 2024.

• Gross profit was $4.70 million for fiscal year 2025, compared to $4.82 million for fiscal year 2024.

• Gross profit margin was 0.6% for fiscal year 2025, compared to 0.7% for fiscal year 2024.

• Net loss was $1.45 million for fiscal year 2025, compared to net income of $2.51 million for fiscal year 2024.
• Net loss attributable to Texxon was $0.93 million for fiscal year 2025, compared to net income attributable to Texxon of $0.95 million for fiscal year 2024.

• Basic and diluted losses per share were $0.05 for fiscal year 2025, compared to basic and diluted earnings per share of $0.05 for fiscal year 2024.

Fiscal Year 2025 Financial Results 

Revenue

Revenue was $797.15 million for fiscal year 2025, representing an increase of 18.5% from $672.66 million for fiscal year 2024.

• Sales of basic chemicals were $524.64 million for fiscal year 2025, representing an increase of 1.5% from $517.03 million for fiscal year 2024. The increase was primarily attributable to an increase in average sales price.
• Sales of plastic particles were $272.39 million for fiscal year 2025, representing an increase of 88.5% from $144.50 million for fiscal year 2024. The increase was primarily attributable to an increase in sales volume.

• Sales of other products were $0.12 million for fiscal year 2025, compared to $11.13 million for fiscal year 2024. The decrease in revenue was primarily attributable to no sales of black metal for the fiscal year 2025, which had contributed approximately $11.0 million revenue from sales of other products for the fiscal year 2024.

Cost of Sales

Cost of sales was $792.45 million for fiscal year 2025, representing an increase of 18.7% from $667.85 million for fiscal year 2024. The increase in cost of sales was largely attributable to the increase in the Company’s sales volume of plastic particles by approximately 188.7 thousand tons, or 138.3%. The increase in cost of sales is in line with the increase in revenue.

Gross Profit and Gross Profit Margin

Gross profit was $4.70 million for fiscal year 2025, compared to $4.82 million for fiscal year 2024.

Gross profit margin was 0.6% for fiscal year 2025, compared to 0.7% for fiscal year 2024. Gross profit and gross margin decreased primarily due to the Company’s strategic shift toward serving major customers, to whom the Company offered more competitive pricing. The Company prioritized expanding business scale and strengthening long-term customer relationships over pursuing short-term high-margin transactions. This strategy temporarily reduced gross margin but is expected to enhance customer retention, stabilize cash flows, and support sustainable profitability growth in the long term.

Operating Expenses

Operating expenses were $5.30 million for fiscal year 2025, representing an increase of 27.5% from $4.16 million for fiscal year 2024.

• Selling expenses were $2.41 million for fiscal year 2025, representing an increase of 21.2% from $1.99 million for fiscal year 2024. The increase in selling expenses was mainly due to (i) salary and welfare benefit expenses increased by approximately $0.3 million mainly due to the addition of marketing personnel to support the Company’s business expansion and higher commissions and bonuses paid to sales staff in connection with the increase in sales; (ii) shipping and delivery expenses increased by approximately $0.1 million, or 7.2%, from approximately $1.0 million for the fiscal year 2024 to approximately $1.1 million for the fiscal year 2025. This increase was primarily due to an increase in sales volume and increased use of third-party shipping services for the sale of plastic particles. The total sales volume of plastic particles increased by 189 thousand tons, or 138.8%, from 136.0 thousand tons for the fiscal year 2024 to 324.8 thousand tons for the fiscal year 2025.

• General and administrative expenses were $2.89 million for fiscal year 2025, representing an increase of 33.3% from $2.17 million for fiscal year 2024. The increase was mainly due to (i) an expected credit loss of approximately $0.7 million for the fiscal year 2025, compared to $1,385 of credit loss recovered for the fiscal year 2024, primarily due to full credit losses established against specific customer receivables following assessment of credit deterioration; and (ii) an increase in salary and welfare benefit expenses of approximately $0.1 million due to an increase in personnel in general and administrative department, (iii) an increase in depreciation and amortization expenses of approximately $0.1 million, partially offset by (iv) a decrease in professional services fee of approximately $0.2 million.
• Other expenses were $1.37 million for fiscal year 2025, compared to other income of $2.57 million for fiscal year 2024. The decrease was primarily attributable to one-time government grants of approximately $2.9 million received in connection with the construction of Henan Polystyrene Factory, which are recognized as a reduction of the cost of construction in progress rather than as other income.

Net Income (loss)

Net loss was $1.45 million for fiscal year 2025, compared to net income of $2.51 million for fiscal year 2024. Net loss attributable to Texxon was $0.93 million for fiscal year 2025, compared to net income attributable to Texxon of $0.95 million for fiscal year 2024.

Basic and Diluted Earnings (losses) per Share

Basic and diluted losses per share were $0.05 for fiscal year 2025, compared to basic and diluted earnings per share of $0.05 for fiscal year 2024.

Financial Condition

As of June 30, 2025, the Company had cash and cash equivalents of $2.52 million, an increase from $0.27 million as of June 30, 2024.

Net cash provided by operating activities was $2.32 million for fiscal year 2025, compared to net cash used in operating activities of $30.80 million for fiscal year 2024.

Net cash used in investing activities was $42.25 million for fiscal year 2025, compared to $11.02 million for fiscal year 2024.

Net cash provided by financing activities was $41.36 million for fiscal year 2025, compared to $29.36 million for fiscal year 2024.

Recent Development

On October 23, 2025, the Company completed its initial public offering (the “Offering”) of 1,900,000 ordinary shares at a public price of US$5.00 per share. On October 28, 2025, the underwriters of the Offering fully exercised their over-allotment option to purchase an additional 285,000 ordinary shares of the Company at the public offering price of US$5.00 per share. The gross proceeds were US$10,925,000 from the Offering, before deducting underwriting discounts and commissions, and other expenses. The Company’s ordinary shares began trading on the Nasdaq Capital Market on October 22, 2025, under the ticker symbol “NPT.”

About Texxon Holding Limited

Texxon Holding Limited is a leading provider of supply chain management services in the plastics and chemical industries in East China. Through its technology-enabled platform, the Company provides a full spectrum of services to Chinese SME customers, including procurement, shipping and logistics, payments and fulfillment services. It aspires to build the largest one-stop plastic and chemical raw material supply chain management platform in China, to streamline the complex and labor-intensive raw material procurement process and enhance convenience, cost-effectiveness, and efficiency for customers. Texxon has built a highly scalable distributed software architecture for continuous improvement, and an effective User Experience Design (UED) process to improve the customer experience. In addition, with over a decade of experience, the Company has amassed substantial transaction data, including supplier and customer information, price trends, category-specific price indexes and market demand volume, to analyze price trends and market demands and make informed decisions. For more information, please visit the Company’s website: ir.npt-cn.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, including, but not limited to, the timeline and effects regarding the construction and production of the Henan Polystyrene Factory. These forward-looking statements involve known and unknown risks and uncertainties related to market conditions, and other factors discussed in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the fiscal year ended June 30, 2025 filed with the U.S. Securities and Exchange Commission (the “SEC”) and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s latest annual report on Form 20-F and other filings with the SEC. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov.

For more information, please contact:

Texxon Holding Limited
Investor Relations Department
Email: ir@totrade.cn

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com 

SYDNEY, Nov. 19, 2025 /PRNewswire/ — Kazia Therapeutics Limited (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with stage IV triple-negative breast cancer (TNBC) treated under an FDA-authorized single-patient expanded access protocol combining paxalisib with pembrolizumab (Keytruda®) and standard chemotherapy has achieved an initial immune-complete response (iCR) per iRECIST criteria. This outcome suggests a profound radiologic response in a highly aggressive metastatic cancer subtype.

This development builds upon Kazia’s October 2, 2025 announcement reporting an 86% reduction in tumor burden after only three weeks of treatment in the same patient. A PET/CT scan performed after approximately three months of therapy demonstrated complete metabolic resolution of all previously identified lesions, consistent with an initial iCR. The patient remains on therapy and under active clinical monitoring. A follow-up scan will be conducted in accordance with immune-based response assessment guidelines to confirm the initial scan.

Complete responses in stage IV metastatic TNBC are exceedingly uncommon across many therapeutic classes, including immunotherapy, chemotherapy, and antibody–drug conjugates. For example, pembrolizumab monotherapy has demonstrated complete response rates of approximately 0.6–4% in metastatic TNBC across KEYNOTE studies, and even the most active approved agents—such as sacituzumab govitecan—have reported complete response rates of only ~2–4% in large Phase 2 and Phase 3 trials.

In this setting, any radiologic finding consistent with an immune-complete response (iCR), even prior to confirmatory imaging, represents a highly unusual event which stands out relative to historical benchmarks for metastatic TNBC. These data may suggest enhanced biological activity of the combination regimen and warrant continued follow-up under iRECIST guidelines.

“Observing an initial complete response in a patient with metastatic triple-negative breast cancer is an extremely encouraging clinical finding,” said Dr. John Friend, Chief Executive Officer of Kazia Therapeutics. “Although this is a single expanded-access case and requires confirmatory imaging, the depth of response aligns closely with our mechanistic hypothesis that paxalisib may meaningfully enhance anti-tumor immunity when combined with checkpoint blockade. This outcome further energizes our Phase 1b program in advanced breast cancer and complements significant progress across our broader pipeline.”

Q4 BUSINESS UPDATE

1. Kazia Announces upcoming presentations related to paxalisib and NDL2 programs

Kazia is pleased to announce the acceptance of two scientific presentations at the 2025 Brisbane Cancer Conference, scheduled to take place on 27–28 November 2025 in Brisbane, Australia.

The Brisbane Cancer Conference is a premier oncology meeting that brings together leading international researchers, clinicians and industry experts working in the fields of translational oncology, molecular medicine and cellular therapeutics.

The following presentations will take on November 27, 2025:

“From bench to bedside: targeting epigenetic pathways to overcome metastasis and immunotherapy resistance in TNBC” – Sudha Rao, PhD, QIMR Berghofer (Australia)

Epigenetic checkpoint blockade: A new booster to enhance immunogenicity” Sherry Tu, PhD, QIMR Berghofer (Australia)

Kazia is proud to announce acceptance of two scientific presentations at the 2025 San Antonio Breast Cancer Symposium (SABCS) to be held December 10–14, 2025. SABCS is the largest and most influential breast cancer meeting globally, drawing more than 10,000 international experts in clinical oncology, translational science, immunotherapy, and molecular diagnostics.

December 10, 2025 — PS2-10-02

“Liquid Biopsy Tracking of PI3K-mTOR Residual Disease Signatures in Metastatic Breast Cancer”, Presenter: Prof. Sudha Rao, QIMR Berghofer (Australia)

December 12, 2025 — PS5-08-04

“A Phase 1b, Multi-Centre, Open-Label, Randomized Study to Evaluate the Safety, Tolerability, and Clinical Activity of Combining Paxalisib with Olaparib or Pembrolizumab/Chemotherapy in Patients with Advanced Breast Cancer”, Presenter: Dr. Michelle Nottage, The Royal Brisbane and Women’s Hospital (Australia)

“SABCS is the pinnacle global meeting for breast cancer research. Being selected for two presentations is both an honor and a strong validation of our scientific direction,” stated Dr. Friend.

2. NDL2 PD-L1 Degrader Program: Advancing Toward IND-Enabling Studies anticipated in Early 2026

As announced in September 2025, Kazia entered into a collaboration and licensing agreement with QIMR Berghofer covering the first in class NDL2 PD-L1 degrader program. PD-L1 degraders represent the next frontier in immuno-oncology, using a dual-mechanism approach is designed to specifically recognize and degrade the resistant, post-translationally modified forms of the PD-L1 protein. This strategy may address resistance mechanisms that limit current checkpoint inhibitors. Kazia expects to initiate IND-enabling preclinical studies in early 2026.

3. GBM Program: Advancing Toward a FDA Type C Meeting Request Following Strong Overall Survival Signals

As detailed in the October 24, 2025 press release, Kazia intends to request a follow-up Type C meeting with the FDA to discuss the overall survival paxalisib findings from our completed clinical studies, alignment with the Project FrontRunner framework, potential requirements for a confirmatory study, and elements needed for a possible NDA submission pathway for paxalisib in newly diagnosed glioblastoma. 

“We believe paxalisib’s OS data strongly justify continued engagement with the FDA and may support a more efficient regulatory strategy under Project FrontRunner,” stated Dr. Friend.

4. As previously disclosed, Kazia received a notice (the “Notice”) from the Listing Qualifications department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) on May 12, 2025 notifying the Company that from March 28, 2025 to May 9, 2025, the Company’s Market Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), Nasdaq provided the Company with 180 calendar days, or until November 10, 2025 to regain compliance with the MVLS Requirement.

On November 12, 2025, Kazia received a staff determination letter (“Staff Letter”) from the Staff of Nasdaq indicating that the Company had not regained compliance with the MVLS Requirement by November 10, 2025. Pursuant to the Nasdaq Listing Rules and the Staff Letter, unless the Company timely requests a hearing before a Hearings Panel (the “Panel”), the Company’s American Depositary Shares would be subject to suspension/delisting . The Staff Letter has no immediate effect on listing or trading, and the Company intends to timely request a hearing before the Panel, which will automatically stay any suspension or delisting action pending the outcome of the hearing.  The Company believes there are remedies available to potentially stop the proceedings and is evaluating corporate and market-based options, including alternative Nasdaq equity requirements to regain compliance.

For investor and media, please contact Alex Star, Managing Director LifeSci Advisors LLC,  Astarr@lifesciadvisors.com, +1-201-786-8795.

About Kazia Therapeutics

Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia. Our lead program is paxalisib, an investigational brain penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed Phase 2/3 study in glioblastoma (GBM-Agile) was reported in 2024 and discussions are ongoing for designing and executing a pivotal registrational study in pursuit of a standard approval. Other clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S. Food and Drug Administration (FDA) in February 2018, and Fast Track Designation (FTD) for glioblastoma by the FDA in August 2020. Paxalisib was also granted FTD in July 2023 for the treatment of solid tumor brain metastases harboring PI3K pathway mutations in combination with radiation therapy. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020, and for atypical teratoid / rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumor types and has provided evidence of synergy with immuno-oncology agents. A Phase I study has been completed and preliminary data was presented at 15th Biennial Ovarian Cancer Research Symposium in September 2024. For more information, please visit www.kaziatherapeutics.com or follow us on X @KaziaTx.

Forward-Looking Statements

This announcement contains forward-looking statements, which can generally be identified as such by the use of words such as “may,” “will,” “plan,” “intend,” “estimate,” “future,” “forward,” “potential,” “anticipate,” or other similar words. Any statement describing Kazia’s future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward looking statements, including, but not limited to, statements regarding: additional confirmatory imaging and analysis to be performed on the TNBC patient treated with paxalisib and pembrolizumab (Keytruda®), the potential benefits of NDL2 and the plans and goals of developing NDL2 formulation, the anticipated development pathways and combinations of NDL2, the timing for results and data related to Kazia’s clinical and preclinical trials, the upcoming scientific presentations, Kazia’s intention to request and hold a Type C meeting with the FDA to discuss OS findings in GBM patients treated with paxalisib and to seek agency feedback on a potential regulatory pathway, the plan to propose initiation of the post-approval, randomized Phase 3 confirmatory study prior to submission of the NDA, the intention to present survival analyses, supporting clinical safety and planned confirmatory trial design for FDA discussion, Kazia’s intention to reference Project FrontRunner principles in its Type C briefing package, the objective to work collaboratively with the FDA under the guiding principles of Project FrontRunner, the plan to pursue a conditional approval in the front-line treatment setting of GBM, the plan to initiate the post-approval, randomized Phase 3 study prior to filing the NDA, the goal of ensuring that Kazia’s development plan and regulatory strategy fully reflects and aligns with the FDA’s framework and emphasis, the timing for results and data related to Kazia’s clinical and preclinical trials, Kazia’s strategy and plans with respect to its paxalisib program, the potential benefits of paxalisib, timing for any regulatory submissions or discussions with regulatory agencies and the potential market opportunity for paxalisib, regaining compliance with the MVLS Requirement and any other Nasdaq listing requirements, the timing and likelihood of requesting and successfully completing a hearing before the Panel and maintaining Kazia’s listing on Nasdaq. Such statements are based on Kazia’s current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties associated with clinical and preclinical trials and product development, including the risk that interim or early data may not be consistent with final data, risks related to regulatory approvals, risks related to the impact of global economic conditions, and risks related to Kazia’s ability to regain and/or maintain compliance with the applicable Nasdaq continued listing requirements and standards. These and other risks and uncertainties are described more fully in Kazia’s most recent Annual Report on form 20-F filed with the SEC, and in subsequent filings with the United States Securities and Exchange Commission. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement.